High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 5, 2008, Pages 466-470

  Wludarski, Sheila C L ^a   Bacchi, Carlos E ^a  

^a Consultoria Em Patologia ^*  (Brazil)

Author keywords

Breast carcinoma; FISH; HER2; HercepTest; SP3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; SP3 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ARTICLE; BREAST CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; ONCOGENE NEU; PREDICTION AND FORECASTING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ANIMAL; BREAST TUMOR; CANCER INVASION; CHEMISTRY; IMMUNOLOGY; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RABBIT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 55949095306     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318162625c     Document Type: Article

References (32)

1. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(suppl 2):1-13. (Pubitemid 33033419)
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science. 1987;235:177-182.
4. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer [review]. Am J Clin Pathol. 1999;112:S53-S67. (Pubitemid 30219464)
5. Wright C, Nicholson S, Angus B, et al. Relationship between cerbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118-121.
6. Fornier M, Esteva FJ, Seudman AD. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol. 2000;27(6 suppl 11):38-45; discussion 92-100. (Pubitemid 32172255)
7. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
8. Slamon DJ, Leyland-Jones B, Shank S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
9. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004;22: 1071-1077.
10. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol. 2002;20: 719-726. (Pubitemid 34111379)
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
12. Hammock L, Lewis M, Phillips C, et al. HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol. 2003;34:1043-1047. (Pubitemid 37315257)
13. Yasiji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291: 1972-1977. (Pubitemid 38544278)
14. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:411-417.
15. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3110.
16. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182. (Pubitemid 36245750)
17. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
18. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664. (Pubitemid 30816223)
19. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
20. Zarbo RJ, HammondME. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;127:549-553.
21. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5:63-69.
22. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007;15: 94-102. (Pubitemid 46673324)
23. Kulka J, Tô ké s AM, Kaposi-Nová k P, et al. Detection of HER-2/ neu gene amplification in breast carcinomas using quantitative real-time PCR-a comparison with immunohistochemical and FISH results. Pathol Oncol Res. 2006;12:197-204.
24. Ainsworth R, Bartlett JM, Going JJ, et al. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol. 2005;58:1086-1090. (Pubitemid 41416060)
25. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17: 1974-1982. (Pubitemid 29318824)
26. Rossi E, Ubiali A, Cadei M, et al. HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH). Appl Immunohistochem Mol Morphol. 2006;14:127-131. (Pubitemid 43941173)
27. Ellis IO, Bartlett J, Dowsett M, et al. Best practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004;57:233-237.
28. Hanna W, O'malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol. 2007;14:149-153.
29. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index. Stat Med. 1996;15:969-986. (Pubitemid 26168321)
30. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
31. Goldman L. Quantitative aspects of clinical reasoning. In: Isselbacher KJ, Braunwald E, eds. Harrison's Principles of Internal Medicine. Chapter 10. 13th ed. Copenhagen N, Denmark: McGraw-Hill; 1994:43-48.
32. Young KD, Lewis RJ. What is confidence? Part 2: detailed definition and determination of confidence intervals. Ann Emerg Med. 1997;30:311-318. (Pubitemid 27371873)